Market Snapshot
| Study Period: | 2018 - 2026 |
| Base Year: | 2020 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | 5.8 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The high growth rate for Metabolomics is primarily due to its high demand in scientific communities for better analysis of diseases, biological processes, and growing applications in healthcare. There are a growing number of research universities collaborating with companies in developed markets, which use a combination of separation and detection techniques, such as Gas chromatography–mass spectrometry (GC-MS), for metabolite profiling of large sets of drugs for diagnosis and treatment of several chronic diseases, like diabetes mellitus. These researches are often recognized at the national level, and governments with private equity partners provide funds for more research toward drug discovery, biomarkers, and other related studies.
Scope of the Report
Metabolomics represents a systematic study of unique chemical processes inside the cells, which involve metabolites. The collection of entire metabolites in a biological cell, tissue, organ, or organism is called metabolome, which are the end products of cellular processes. In the past one decade, the scientific communities across the world have been integrating proteomic, transcriptomic, and metabolomic information, which helps in the early analysis of any chronic genetic or infectious diseases. These are funded by several private and public funding, which helps in the growth of the metabolomics market.
| By Metabolite Analysis | ||||||||||||
| ||||||||||||
| Bioinformatics Tools and Database |
| By Application | |
| Biomarker and Drug Discovery | |
| Toxicology | |
| Nutrigenomics | |
| Personalized Medicine | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Key Market Trends
Biomarker and Drug Discovery Segment, under Application, is Expected to Hold the Highest Revenue
Metabolomics focuses mainly on profiling small-molecule metabolites (metabolic profiling), and differ from genomics and proteomics, which characterize the profiles of genes and proteins, respectively. Additionally, biomarkers are the objective and quantitatively-measurable indicators of biological or pathogenic processes. Both metabolomics and biomarkers are progressively used in drug discovery and development, managing disease progression, especially for personalized or precision medicine. Metabolomics and biomarkers are likely to advance drug development and personalized therapy in the future, mainly in highly demanding disease areas, such as cardiovascular and metabolic diseases, cancer, mental health, and other infectious diseases. The increasing challenges faced by the pharmaceutical industry, such as dwindling discovery pipelines, limited budget sanctioned for a particular R&D, increasing regulatory control, significant gaps in the future drug markets, are expected to drive the growth of the market.
To understand key trends, Download Sample Report
North America Dominates the Market and is Expected to do Same during the Forecast Period
North America is expected to dominate the market, over other regions, throughout the forecast period. The presence of high per capita healthcare expenditure, increasing adoption rate of healthcare technology, well-established direct sales channel across the region, and a continuous boost to small and mid-sized metabolomics-oriented research communities and companies, globally, from the National Institutes of Health (NIH) program, help in the growth of metabolomics business.
To understand geography trends, Download Sample Report
Competitive Landscape
The metabolomics market is moderately competitive and consists of several major players. In terms of the market share, few of the major players currently dominate the market. The major global companies, such as Thermofisher, Bruker Corporation, and Agilent Technologies, are increasing collaboration with educational societies and research communities, funding them for more research with combination, separation, and detection technique licenses. With the specific requirements to metabolite research, the HPLC and UPLC are increasingly preferred over other techniques for its most versatile separation method. Several pharmaceutical companies prefer research institutes for characterizing toxicological studies, to develop new drugs against infectious diseases. The technical advancements and combination with MS and NMR are being rapidly adopted, globally. These segments, thus, primarily drive the market.
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Rising Demand for Personalized Medicines
-
4.2.2 High Investments by Public and Private Sectors in the Field of Metabolomics
-
4.2.3 Rising Need for Early and Accurate Diagnosis of Diseases
-
-
4.3 Market Restraints
-
4.3.1 High Cost of Tools and Instruments
-
4.3.2 Lack of Skilled Professionals
-
-
4.4 Porter's Five Forces Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Metabolite Analysis
-
5.1.1 Analytical Techniques
-
5.1.1.1 Separation Techniques
-
5.1.1.1.1 Liquid Chromatography
-
5.1.1.1.2 Gas Chromatography
-
5.1.1.1.3 Capillary Electrophoresis
-
-
5.1.1.2 Detection Techniques
-
5.1.1.2.1 Mass Spectrometry
-
5.1.1.2.2 Nuclear Magnetic Resonance Spectroscopy
-
5.1.1.2.3 Other Detection Techniques
-
-
-
5.1.2 Bioinformatics Tools and Database
-
-
5.2 By Application
-
5.2.1 Biomarker and Drug Discovery
-
5.2.2 Toxicology
-
5.2.3 Nutrigenomics
-
5.2.4 Personalized Medicine
-
5.2.5 Other Applications
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia-Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South Korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle East & Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle East & Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Agilent Technologies
-
6.1.2 Bio-Rad Laboratories Inc.
-
6.1.3 Bruker Corporation
-
6.1.4 Danaher Corporation (SCIEX)
-
6.1.5 LECO Corporation
-
6.1.6 Shimadzu Corporation
-
6.1.7 Thermo Fisher Scientific
-
6.1.8 Waters Corporation
-
6.1.9 PerkinElmer Inc.
-
6.1.10 Kore Technology Limited
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Metabolomics Market market is studied from 2018 - 2026.
What is the growth rate of Metabolomics Market?
The Metabolomics Market is growing at a CAGR of 5.8% over the next 5 years.
Which region has highest growth rate in Metabolomics Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Metabolomics Market?
North America holds highest share in 2020.
Who are the key players in Metabolomics Market?
Thermo Fisher Scientific Inc., Bruker Corporation, Bio-Rad Laboratories, Agilent Technologies Inc., Danaher Corporation are the major companies operating in Metabolomics Market.
